Could safety scupper Ionis, Pfizer’s cholesterol drug vupanorsen?Ionis has reported phase 2b trial data for its Pfizer-partnered antisense drug vupanorsen for cholesterol lowering that showed Share XCould safety scupper Ionis, Pfizer’s cholesterol drug vupanorsen?https://pharmaphorum.com/news/could-safety-scupper-ionis-pfizers-cholesterol-drug-vupanorsen/
AZ, Moderna say mRNA drug is promising in heart failureModerna is already riding high on the strength of its mRNA-based COVID-19 vaccine, but the broader potential of Share XAZ, Moderna say mRNA drug is promising in heart failurehttps://pharmaphorum.com/news/az-moderna-say-mrna-drug-is-promising-in-heart-failure/
Smartphone-powered trial backs J&J’s Invokana for heart failureJohnson & Johnson’s SGLT2 inhibitor Invokana has been shown to have a significant effect on heart failure symptoms Share XSmartphone-powered trial backs J&J’s Invokana for heart failurehttps://pharmaphorum.com/news/smartphone-powered-trial-backs-jjs-invokana-for-heart-failure/
AZ closes $400 million Atacand sale to Germany’s CheplapharmAstraZeneca has completed the sell-off of another mature product, hiving off its Atacand cardiovascular franchise to Cheplapharm as Share XAZ closes $400 million Atacand sale to Germany’s Cheplapharmhttps://pharmaphorum.com/news/az-closes-400-million-atacand-sale-to-germanys-cheplapharm/
FDA grants fast review of AZ’s Brilinta to prevent recurring strokesThe FDA has granted a fast review of AstraZeneca’s cardiovascular diseases drug Brilinta (ticagrelor) in the new indication that aims to reduce Share XFDA grants fast review of AZ’s Brilinta to prevent recurring strokeshttps://pharmaphorum.com/news/az-grants-fast-review-of-astrazenecas-cardiovascular-diseases-drug-brilinta/
AZ claims FDA okay for Brilinta in coronary artery disease patientsAstraZeneca’s anti-platelet drug Brilinta has been cleared in the US for a major new indication, preventing a first Share XAZ claims FDA okay for Brilinta in coronary artery disease patientshttps://pharmaphorum.com/news/az-claims-fda-okay-for-brilinta-in-coronary-artery-disease-patients/
FDA approves new heart failure use for AZ’s FarxigaThe FDA has approved a new use for AstraZeneca’s Farxiga (dapagliflozin) to reduce risk of cardiovascular death and hospitalisation with heart failure, in Share XFDA approves new heart failure use for AZ’s Farxigahttps://pharmaphorum.com/news/fda-approves-new-heart-failure-use-for-azs-farxiga/
AstraZeneca on expanding its diabetes research franchiseAstraZeneca is hoping to build a strong focus on cardiovascular, renal, and metabolic (CVRM) diseases. Richard Staines spoke Share XAstraZeneca on expanding its diabetes research franchisehttps://deep-dive.pharmaphorum.com/magazine/research-and-development-disruption-2020/astrazeneca-takes-on-cvrm/
Amarin hit hard as generics loom for fish oil drug VascepaGeneric drugmakers Hikma and Dr Reddy’s Laboratories have won a surprise victory in a US patent lawsuit that Share XAmarin hit hard as generics loom for fish oil drug Vascepahttps://pharmaphorum.com/news/amarin-hit-hard-as-generics-loom-for-fish-oil-drug-vascepa/
